Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
NCT06700720

YN001-004 in Patients With Coronary Atherosclerosis in Australia

Led by Beijing Inno Medicine Co., Ltd. · Updated on 2026-02-17

24

Participants Needed

7

Research Sites

17 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study is to evaluate the efficacy and safety of intravenously administered YN001 in patients with coronary atherosclerosis in Australia. This study will be conducted in eligible participants with a diagnosis of coronary atherosclerosis, and at least 1 coronary artery is blocked determined by coronary computed tomography angiography (CCTA)

CONDITIONS

Official Title

YN001-004 in Patients With Coronary Atherosclerosis in Australia

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Understand the study purpose, methods, and sign informed consent before any assessments
  • Male or female patients aged 18 to 75 years in Australia
  • Diagnosed with coronary atherosclerosis with at least one vessel blocked as shown by coronary CTA
  • Female patients must not be pregnant or breastfeeding and must use effective contraception from screening until 3 months after last dose; male patients must agree to avoid sperm donation during this time
  • Willing and able to follow the study protocol requirements to the best of their and investigators' knowledge
Not Eligible

You will not qualify if you...

  • Received other investigational drugs within 30 days or 5 half-lives before randomization
  • Previously treated with YN001
  • Received any vaccination within 4 weeks before randomization
  • Contraindicated for coronary CTA (e.g., history of severe allergic reactions to contrast)
  • Multi-vessel severe coronary disease
  • Recent acute STEMI within 2 weeks before randomization
  • Uncontrolled symptomatic arrhythmia in the last 3 months
  • Prior or planned heart surgeries such as CABG, heart transplant, SAVR/TAVR
  • PCI done within 4 weeks before randomization or planned during study
  • NYHA class III or IV heart failure or last known LVEF below 40%
  • Stroke within 6 months before randomization (except TIA)
  • History or risk of muscle disease such as myopathy or rhabdomyolysis
  • Known inflammatory bowel disease or recent gastrointestinal bleeding
  • Major diseases not recovered within 2 weeks before randomization or planned major surgery
  • History of cancer unless disease-free for over 5 years or only basal/squamous skin cancer
  • Any autoimmune disease
  • Allergies to multiple foods or drugs or sensitivity to study drug components
  • Life expectancy under 1 year
  • Systolic blood pressure 150 mmHg or higher despite medication
  • Known familial hypercholesterolemia
  • Triglycerides 400 mg/dl or higher at screening
  • Active liver disease or liver function tests over twice the normal limit
  • Renal insufficiency
  • Untreated or poorly treated hypothyroidism
  • Poorly controlled type 2 diabetes (HbA1c over 9%)
  • Positive tests for hepatitis B, hepatitis C, HIV, or syphilis
  • Current smoker averaging 5 or more cigarettes per day over the past year
  • Other diseases or conditions making participation unsuitable per investigator's judgment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 7 locations

1

Canberra Hospital

Canberra, Australian Capital Territory, Australia

Actively Recruiting

2

Albury Wodonga Private Hospital

Albury, New South Wales, Australia, 1125

Actively Recruiting

3

Sunshine Coast University Private Hospital

Birtinya, Queensland, Australia, 4575

Actively Recruiting

4

Core Research Group Pty Ltd

Milton, Queesland, Australia

Withdrawn

5

Altona Clinical Research

Melbourne, Victoria, Australia, 3025

Actively Recruiting

6

Peninsula Heart Centre

Melbourne, Victoria, Australia, 3199

Actively Recruiting

7

John Flynn Private Hospital

Tugun, Australia

Not Yet Recruiting

Loading map...

Research Team

J

Jean Zhang

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here